1. Show article details.

    What Apple, Microsoft, Nike and other U.S. companies are saying about the coronavirus outbreak

    MarketWatch – 11:01 AM ET 02/27/2020

    By Ciara Linnane, MarketWatch, Jaimy Lee. Coronavirus is the dominant theme in earnings releases and on companies' conference calls as investors seek to gauge its impact on corporate results. COVID-19, the disease caused by the new coronavirus that was first identified late last year in Wuhan, China, has been a dominant theme in the earnings releases and conference calls of S&P 500 companies as investors press for answers on how it will impact their financials.

  2. Show article details.

    US STOCKS-Wall St set for steep fall on alarm over fast-spreading virus

    Reuters – 9:09 AM ET 02/27/2020

    * Three main stock indexes down in the past five sessions. * GS estimates zero U.S. company earnings growth in 2020. * Futures down: Dow 1.24%, S&P 1.30%, Nasdaq 1.46% By Medha Singh.

  3. Show article details.

    US STOCKS-Futures slump on alarm over fast-spreading virus

    Reuters – 8:08 AM ET 02/27/2020

    * Futures down: Dow 1.36%, S&P 1.30%, Nasdaq 1.52% By Medha Singh. U.S. stock index futures dropped more than 1% on Thursday as investors stayed away from making riskier bets after the rapid spread of the coronavirus outside China deepened worries about growth and corporate earnings.

  4. Show article details.

    PRESS DIGEST- New York Times business news - Feb. 27

    Reuters – 1:43 AM ET 02/27/2020

    The following are the top stories on the New York Times business pages. - Drugmaker Gilead Sciences Inc is expanding its clinical trials of the antiviral drug remdesivir as a possible coronavirus treatment into several countries outside China, the company announced on Wednesday. https://nyti.ms/3aaih6o.

  5. Show article details.

    Coronavirus spreads faster outside China, stoking global fears

    Reuters – 7:03 PM ET 02/26/2020

    * Cases detected for first time in Brazil, Pakistan, Greece. * New York monitoring dozens of people, no cases confirmed. * Global markets fall further. * Interactive graphic tracking global spread of coronavirus: open https://tmsnrt.rs/3aIRuz7 in an external browser. By David Stanway and Josh Smith.

  6. Show article details.

    BRIEF-Gilead Sciences Initiates Two Phase 3 Studies Of Investigational Antiviral Remdesivir For The Treatment Of Covid-19

    Reuters – 5:37 PM ET 02/26/2020

    Gilead Sciences Inc (GILD): * GILEAD SCIENCES INITIATES TWO PHASE 3 STUDIES OF INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR THE TREATMENT OF COVID-19. * Gilead Sciences Inc (GILD) - U.S. FDA GRANTS INVESTIGATIONAL NEW DRUG AUTHORIZATION TO STUDY REMDESIVIR FOR TREATMENT OF COVID-19. * Gilead Sciences Inc (GILD) - GILEAD STUDIES WILL EVALUATE TWO DOSING DURATIONS OF REMDESIVIR.

  7. Show article details.

    Gilead to Kick Off Its Own Studies of Potential Coronavirus Drug

    DJ Business News – 5:35 PM ET 02/26/2020

    Gilead Sciences Inc. (GILD) said Wednesday it would start late-stage studies of its experimental treatment for the coronavirus in March, an acceleration of its push to evaluate what it hopes could be the first medicine specifically approved to treat the respiratory disease. Gilead said it will conduct two studies with a total of 1,000 patients across mainly Asian countries, as well as other nations with high numbers of diagnosed patients. Gilead is kicking off the studies following...

  8. Show article details.

    Gilead announces more trials for drug aimed at COVID-19, stock up 4%

    MarketWatch – 5:21 PM ET 02/26/2020

    Shares of Gilead Sciences Inc. (GILD) rose nearly 4% in the extended session Wednesday after the pharma company said it had started two clinical studies to gauge the safety and efficacy of its remdesivir drug in adults diagnosed with COVID-19. Beginning in March, the studies will enroll about 1,000 patients at medical centers primarily in Asian countries as well as countries with a high numbers of diagnosed cases, Gilead said in a statement. The initiation of these studies follows the...

  9. Show article details.

    Gilead starts 2 late-stage studies to test drug for coronavirus

    Reuters – 5:12 PM ET 02/26/2020

    Gilead Sciences Inc (GILD) said on Wednesday it has started two late-stage studies to test its drug in patients with coronavirus. Beginning March, the studies will test the drug, remdesivir, among approximately 1,000 patients at medical centers primarily across Asian countries, as well as in other countries with high numbers of diagnosed cases, the company said https://reut.rs/2wQhEjX.

  10. Show article details.

    Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19

    Business Wire – 5:00 PM ET 02/26/2020

    -- U.S. FDA Grants Investigational New Drug Authorization to Study Remdesivir for the Treatment of COVID-19 -- Gilead Sciences, Inc. (GILD) today announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19.

  11. Show article details.

    U.S. health officials urge Americans to prepare for spread of coronavirus

    Reuters – 9:52 PM ET 02/25/2020

    The U.S. Centers for Disease Control and Prevention on Tuesday alerted Americans to begin preparing for the spread of coronavirus in the United States after infections surfaced in several more countries.

  12. Show article details.

    First U.S. Testing Begins for Potential Coronavirus Treatment

    DJ Business News – 5:59 PM ET 02/25/2020

    Researchers have begun the first study in the U.S. of an experimental drug aimed at treating the novel coronavirus, the National Institutes of Health said Tuesday. Researchers at the University of Nebraska have started testing an experimental antiviral drug from Gilead Sciences Inc. (GILD), the NIH said. The first U.S. study subject is an American who is among 13 passengers who were quarantined on the Diamond Princess cruise ship and transported recently to the University of Nebraska...

  13. Show article details.

    U.S. health officials urge Americans to prepare for spread of coronavirus

    Reuters – 4:21 PM ET 02/25/2020

    The U.S. Centers for Disease Control and Prevention on Tuesday alerted Americans to begin preparing for the spread of coronavirus in the United States after infections surfaced in several more countries.

  14. Show article details.

    BRIEF-HHS Secretary Azar:"We might have to take community mitigation" measures if coronavirus cases increase

    Reuters – 4:04 PM ET 02/25/2020

    * CDC official Schuchat says believes immediate risk from coronavirus in U.S. remains low. * CDC official Schuchat says "no longer a question of if" a coronavirus pandemic will happen, but when it will happen. * NIH's Fauci says a possible coronavirus vaccine could be tested in humans in a phase 1 trial within a month and a half.

  15. Show article details.

    BRIEF-NIH Says Clinical Trial Of Remdesivir To Treat Covid-19 Begins Study Enrolling

    Reuters – 2:02 PM ET 02/25/2020

    NIH: * NIH - CLINICAL TRIAL OF REMDESIVIR TO TREAT COVID-19 BEGINS STUDY ENROLLING HOSPITALIZED ADULTS WITH COVID-19 IN NEBRASKA. * NIH - ALTHOUGH REMDESIVIR HAS BEEN ADMINISTERED TO SOME PATIENTS WITH COVID-19, DO NOT HAVE SOLID DATA TO INDICATE IT CAN IMPROVE CLINICAL OUTCOMES.

  16. Show article details.

    U.S. begins first coronavirus clinical trial testing Gilead's experimental drug

    Reuters – 11:37 AM ET 02/25/2020

    U.S. health officials said on Tuesday the first clinical trial testing Gilead Sciences Inc's (GILD) experimental antiviral drug, remdesivir, in hospitalized patients with the coronavirus has started.

  17. Show article details.

    US STOCKS-Wall St plunges on fears of coronavirus pandemic

    Reuters – 5:02 PM ET 02/24/2020

    * Indexes drop: Dow 3.56%, S&P 3.35%, Nasdaq 3.71% * Energy, technology stocks lead the slide. * Wall Street's fear gauge surges to over 1-yr high. * Health insurers fall after Sanders' Nevada victory. By Sinéad Carew.

  18. Show article details.

    US STOCKS-Wall Street sinks as pandemic fears rattle investors

    Reuters – 3:07 PM ET 02/24/2020

    * Indexes drop: Dow 3.2%, S&P 3.05%, Nasdaq 3.44% * Energy, high-growth technology stocks lead slide. * Wall Street's fear gauge surges to over 1-yr high. * Health insurers fall after Bernie Sanders' Nevada victory. By Sinéad Carew.

  19. Show article details.

    US STOCKS-Dow sinks 1,000 points as pandemic fears rattle Wall Street

    Reuters – 1:36 PM ET 02/24/2020

    * Indexes drop: Dow 3.54%, S&P 3.49%, Nasdaq 3.95% * High-growth technology stocks lead slide. * Wall Street's fear gauge surges to over 1-yr high. * Health insurers fall after Bernie Sanders' Nevada victory. By Medha Singh.

  20. Show article details.

    US STOCKS-Pandemic fears grip Wall Street, Dow dives 800 points

    Reuters – 11:39 AM ET 02/24/2020

    * Indexes drop: Dow 2.81%, S&P 2.69%, Nasdaq 3.20% * High-growth technology stocks lead slide. * Wall Street's fear gauge surges to six-month high. * Health insurers fall after Bernie Sanders' Nevada victory. By Medha Singh.

Page:

Today's and Upcoming Events

  • Apr
    30

    GILD to announce Q1 earnings (Unconfirmed)

  • Mar
    12

    GILD ex-Dividend for $0.68 on 03/12/2020

    • Announce Date: 02/04/2020
    • Record Date: 03/13/2020
    • Pay Date: 03/30/2020

Past Events (last 90 days)

  • Feb
    04

    GILD announced Q4 earnings.

  • Dec
    12

    GILD ex-Dividend for $0.63 on 12/12/2019

    • Announce Date: 10/23/2019
    • Record Date: 12/13/2019
    • Pay Date: 12/30/2019
Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.